Product
Efavaleukin alfa
Aliases
AMG 592
3 clinical trials
2 indications
Indication
Inflammatory DiseasesIndication
ulcerative colitisClinical trial
A Phase 1, Open-label, Sequential-group, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 592 Administered Subcutaneously in Healthy Chinese, Japanese, and Caucasian SubjectsStatus: Completed, Estimated PCD: 2022-10-03
Clinical trial
A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2028-05-31
Clinical trial
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2025-07-23